185 related articles for article (PubMed ID: 34559006)
21. (18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate.
Sachpekidis C; Mai EK; Goldschmidt H; Hillengass J; Hose D; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A
Clin Nucl Med; 2015 Jun; 40(6):e300-7. PubMed ID: 25783508
[TBL] [Abstract][Full Text] [Related]
22. Multi-parametric whole-body MRI evaluation discerns vital from non-vital multiple myeloma lesions as validated by
Heidemeier A; Schloetelburg W; Thurner A; Metz C; Heidemeier H; Rasche L; Martin Kortuem K; Boeckle D; Weiland E; Benkert T; Nickel D; Werner R; Buck AK; Bley TA
Eur J Radiol; 2022 Oct; 155():110493. PubMed ID: 36027759
[TBL] [Abstract][Full Text] [Related]
23. A prospective study comparing whole-body skeletal X-ray survey with 18F-FDG-PET/CT, 18F-NaF-PET/CT and whole-body MRI in the detection of bone lesions in multiple myeloma patients.
Dyrberg E; Hendel HW; Al-Farra G; Balding L; Løgager VB; Madsen C; Thomsen HS
Acta Radiol Open; 2017 Oct; 6(10):2058460117738809. PubMed ID: 29123920
[TBL] [Abstract][Full Text] [Related]
24. Whole-body low-dose CT recognizes two distinct patterns of lytic lesions in multiple myeloma patients with different disease metabolism at PET/MRI.
Zambello R; Crimì F; Lico A; Barilà G; Branca A; Guolo A; Varin C; Vezzaro R; Checuz L; Scapin V; Berno T; Pizzi M; Ponzoni A; De Biasi E; Vio S; Semenzato G; Zucchetta P; Lacognata C
Ann Hematol; 2019 Mar; 98(3):679-689. PubMed ID: 30539276
[TBL] [Abstract][Full Text] [Related]
25. Imaging CXCR4 receptors expression for staging multiple myeloma by using
Shekhawat AS; Singh B; Malhotra P; Watts A; Basher R; Kaur H; Hooda M; Radotra BD
Br J Radiol; 2022 Aug; 95(1136):20211272. PubMed ID: 35731811
[TBL] [Abstract][Full Text] [Related]
26. 99mTc-sestamibi SPECT/CT and 18F-FDG-PET/CT have similar performance but different imaging patterns in newly diagnosed multiple myeloma.
Mosci C; Pericole FV; Oliveira GB; Delamain MT; Takahashi MES; Carvalheira JBC; Etchebehere ECSC; Santos AO; Miranda ECM; Lima MCL; Amorim BJ; de Souza CA; Lorand-Metze I; Ramos CD
Nucl Med Commun; 2020 Oct; 41(10):1081-1088. PubMed ID: 32732603
[TBL] [Abstract][Full Text] [Related]
27. [Informativeness of whole-body diffusion-weighted magnetic resonance imaging and positron emission tomography with computed tomography in follicular lymphoma].
Nesterova ES; Yatsyk GA; Lutsik NS; Kravchenko SK; Sudarikov AB; Krasil'nikova IV; Gemdzhian EG; Kovrigina AM
Ter Arkh; 2020 Sep; 92(7):55-62. PubMed ID: 33346445
[TBL] [Abstract][Full Text] [Related]
28. Imaging of treatment response and minimal residual disease in multiple myeloma: state of the art WB-MRI and PET/CT.
Lecouvet FE; Vekemans MC; Van Den Berghe T; Verstraete K; Kirchgesner T; Acid S; Malghem J; Wuts J; Hillengass J; Vandecaveye V; Jamar F; Gheysens O; Vande Berg BC
Skeletal Radiol; 2022 Jan; 51(1):59-80. PubMed ID: 34363522
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the diagnostic performance and impact on management of 18F-FDG PET/CT and whole-body MRI in multiple myeloma.
Westerland O; Amlani A; Kelly-Morland C; Fraczek M; Bailey K; Gleeson M; El-Najjar I; Streetly M; Bassett P; Cook GJR; Goh V;
Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2558-2565. PubMed ID: 33469686
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic value of WB-DWI versus
Zhang B; Zhang L; Bian B; Lin F; Zhu Z; Wang J
Indian J Cancer; 2023; 60(3):303-309. PubMed ID: 37787189
[TBL] [Abstract][Full Text] [Related]
31. Whole body MRI with Diffusion Weighted Imaging versus 18F-fluorodeoxyglucose-PET/CT in the staging of lymphomas.
Maccioni F; Alfieri G; Assanto GM; Mattone M; Gentiloni Silveri G; Viola F; De Maio A; Frantellizzi V; Di Rocco A; De Vincentis G; Pulsoni A; Martelli M; Catalano C
Radiol Med; 2023 May; 128(5):556-564. PubMed ID: 37145214
[TBL] [Abstract][Full Text] [Related]
32. Prospective Evaluation of Magnetic Resonance Imaging and [
Moreau P; Attal M; Caillot D; Macro M; Karlin L; Garderet L; Facon T; Benboubker L; Escoffre-Barbe M; Stoppa AM; Laribi K; Hulin C; Perrot A; Marit G; Eveillard JR; Caillon F; Bodet-Milin C; Pegourie B; Dorvaux V; Chaleteix C; Anderson K; Richardson P; Munshi NC; Avet-Loiseau H; Gaultier A; Nguyen JM; Dupas B; Frampas E; Kraeber-Bodere F
J Clin Oncol; 2017 Sep; 35(25):2911-2918. PubMed ID: 28686535
[TBL] [Abstract][Full Text] [Related]
33. 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis.
Machado Medeiros T; Altmayer S; Watte G; Zanon M; Basso Dias A; Henz Concatto N; Hoefel Paes J; Mattiello R; de Souza Santos F; Mohammed TL; Verma N; Hochhegger B
Eur Radiol; 2020 Jul; 30(7):3641-3649. PubMed ID: 32125513
[TBL] [Abstract][Full Text] [Related]
34. Whole-body MRI versus an FDG-PET/CT-based reference standard for staging of paediatric Hodgkin lymphoma: a prospective multicentre study.
Spijkers S; Littooij AS; Kwee TC; Tolboom N; Beishuizen A; Bruin MCA; Elias SG; van de Brug T; Enríquez G; Sábado C; Miller E; Granata C; de Lange C; Verzegnassi F; Greer MC; de Keizer B; Nievelstein RAJ
Eur Radiol; 2021 Mar; 31(3):1494-1504. PubMed ID: 32880696
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic performance of FDG-PET/MRI and WB-DW-MRI in the evaluation of lymphoma: a prospective comparison to standard FDG-PET/CT.
Herrmann K; Queiroz M; Huellner MW; de Galiza Barbosa F; Buck A; Schaefer N; Stolzman P; Veit-Haibach P
BMC Cancer; 2015 Dec; 15():1002. PubMed ID: 26699124
[TBL] [Abstract][Full Text] [Related]
36. 18F-FDG PET/CT for detection and localization of residual or recurrent disease in patients with multiple myeloma after stem cell transplantation.
Derlin T; Weber C; Habermann CR; Herrmann J; Wisotzki C; Ayuk F; Wolschke C; Klutmann S; Kröger N
Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):493-500. PubMed ID: 22113619
[TBL] [Abstract][Full Text] [Related]
37. ¹⁸F-FDG PET/CT and 3.0-T whole-body MRI for the detection of distant metastases and second primary tumours in patients with untreated oropharyngeal/hypopharyngeal carcinoma: a comparative study.
Chan SC; Wang HM; Yen TC; Lin CY; Chin SC; Liao CT; Wai YY; Wang JJ; Ng SH
Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1607-19. PubMed ID: 21567252
[TBL] [Abstract][Full Text] [Related]
38. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in the prediction of outcome of patients with multiple myeloma: a comparative study.
Fonti R; Pace L; Cerchione C; Catalano L; Salvatore B; De Luca S; Pane F; Salvatore M; Del Vecchio S
Clin Nucl Med; 2015 Apr; 40(4):303-8. PubMed ID: 25608167
[TBL] [Abstract][Full Text] [Related]
39. Whole body magnetic resonance with diffusion weighted sequence with body signal suppression compared to (18)F-FDG PET/CT in newly diagnosed lymphoma.
Ferrari C; Minoia C; Asabella AN; Nicoletti A; Altini C; Antonica F; Ficco M; Guarini A; Maggialetti N; Rubini G
Hell J Nucl Med; 2014; 17 Suppl 1():40-9. PubMed ID: 24392468
[TBL] [Abstract][Full Text] [Related]
40. Relation of whole-body metabolic tumor volume and total lesion glycolysis on fluorodeoxyglucose PET/computed tomography with clinical and laboratory parameters in newly diagnosed multiple myeloma.
Goksel S; Ilkkilic K; Bulbul O; Akdogan E
Nucl Med Commun; 2022 Oct; 43(10):1077-1083. PubMed ID: 36006402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
